Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

271 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer.
Morita S, Uehara K, Nakayama G, Shibata T, Oguri T, Inada-Inoue M, Shimokata T, Sugishita M, Mitsuma A, Ando Y. Morita S, et al. Among authors: nakayama g. Cancer Chemother Pharmacol. 2013 Feb;71(2):405-11. doi: 10.1007/s00280-012-2028-2. Epub 2012 Nov 17. Cancer Chemother Pharmacol. 2013. PMID: 23161411
The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801).
Nakayama G, Uehara K, Ishigure K, Yokoyama H, Ishiyama A, Eguchi T, Tsuboi K, Ohashi N, Fujii T, Sugimoto H, Koike M, Fujiwara M, Ando Y, Kodera Y. Nakayama G, et al. Cancer Chemother Pharmacol. 2012 Oct;70(4):575-81. doi: 10.1007/s00280-012-1948-1. Epub 2012 Aug 12. Cancer Chemother Pharmacol. 2012. PMID: 22886005 Free PMC article. Clinical Trial.
The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer.
Nakayama G, Tanaka C, Uehara K, Mashita N, Hayashi N, Kobayashi D, Kanda M, Yamada S, Fujii T, Sugimoto H, Koike M, Nomoto S, Fujiwara M, Ando Y, Kodera Y. Nakayama G, et al. Cancer Chemother Pharmacol. 2014 Apr;73(4):847-55. doi: 10.1007/s00280-014-2416-x. Epub 2014 Feb 28. Cancer Chemother Pharmacol. 2014. PMID: 24577566 Clinical Trial.
The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902).
Nakayama G, Ishigure K, Yokoyama H, Uehara K, Kojima H, Ishiyama A, Hayashi N, Takano N, Hattori N, Kobayashi D, Tanaka C, Hayashi M, Kanda M, Yamada S, Sugimoto H, Koike M, Fujiwara M, Fujii T, Murotani K, Ando Y, Kodera Y. Nakayama G, et al. BMC Cancer. 2017 Apr 4;17(1):243. doi: 10.1186/s12885-017-3245-1. BMC Cancer. 2017. PMID: 28376737 Free PMC article. Clinical Trial.
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study.
Oki E, Kato T, Bando H, Yoshino T, Muro K, Taniguchi H, Kagawa Y, Yamazaki K, Yamaguchi T, Tsuji A, Iwamoto S, Nakayama G, Emi Y, Touyama T, Nakamura M, Kotaka M, Sakisaka H, Yamanaka T, Kanazawa A. Oki E, et al. Among authors: nakayama g. Clin Colorectal Cancer. 2018 Jun;17(2):147-155. doi: 10.1016/j.clcc.2018.01.011. Epub 2018 Feb 9. Clin Colorectal Cancer. 2018. PMID: 29530335 Free article. Clinical Trial.
271 results